Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-334174
Filing Date
2026-08-05
Accepted
2026-08-05 10:30:38
Documents
71
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mcrb-20260630.htm   iXBRL 10-Q 2795332
2 EX-10.1 mcrb-ex10_1.htm EX-10.1 43920
3 EX-31.1 mcrb-ex31_1.htm EX-31.1 15244
4 EX-31.2 mcrb-ex31_2.htm EX-31.2 15144
5 EX-32.1 mcrb-ex32_1.htm EX-32.1 9489
6 EX-32.2 mcrb-ex32_2.htm EX-32.2 9396
  Complete submission text file 0001193125-26-334174.txt   9502764

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20260630.xsd EX-101.SCH 1100072
75 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20260630_htm.xml XML 1613134
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37465 | Film No.: 261241824
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)